AI-assisted, human-published
05/02/2024 /Funding Events
Latus Bio Secures $54M in Series A Funding for CNS Gene Therapy Development
Latus Bio has obtained an initial closing of $54 million in Series A funding led by 8VC and DCVC Bio, with plans to develop gene therapies for CNS disorders.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com